Overview
- Editors:
-
-
Benjamin Bonavida
-
Dept. Microbiology, Immunology &, Molecular Genetics, University of California, Los Angeles, Los Angeles, USA
- Describes the main mechanisms that govern tumor cell resistance to apoptotic stimuli
- Demonstrates the identification of existing agents or the development of new agents that can serve as sensitizing agents with other cytotoxics
- Features the latest research on the results of combining targeted sensitizing agents and conventional cytotoxic therapies
Access this book
Other ways to access
Table of contents (13 chapters)
-
Front Matter
Pages i-xiii
-
- Khyati Kapoor, Hong May Sim, Suresh V. Ambudkar
Pages 1-34
-
- Chloe Daniel, Cyril Rauch
Pages 35-46
-
- Alyson K. Freeman, Deborah K. Morrison
Pages 47-67
-
- Ramana V. Tantravahi, Benjamin Hoffman, E. Premkumar Reddy
Pages 69-88
-
- Srirupa Mukhopadhyay, Parth Malik, Sunil Kumar Arora, Tapan K. Mukherjee
Pages 89-108
-
- Toshiyuki Matsunaga, Ossama El-Kabbani, Akira Hara
Pages 109-133
-
-
- Man-Tzu Wang, Hongmei Jiang, Debasish Boral, Daotai Nie
Pages 151-161
-
- Elisa Zucca, Emmanuele Crespan, Federica Bertoletti, Miroslava Kissova, Giovanni Maga
Pages 163-186
-
- Mohamed Saeed, Henry Johannes Greten, Thomas Efferth
Pages 187-211
-
- Anita C. Bellail, Chunhai Hao
Pages 213-243
-
-
-
Back Matter
Pages 259-260
About this book
This volume gives the latest developments in on the mechanisms of cancer cell resistance to apoptotic stimuli, which eventually result in cancer progression and metastasis. One of the main challenges in cancer research is to develop new therapies to combat resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance to cytotoxic drug-induced apoptosis. These mechanisms should reveal gene products that directly regulate resistance in order to develop new drugs that target these resistance factors and such new drugs may either be selective or common to various cancers. If successful, new drugs may not be toxic and may be used effectively in combination with subtoxic conventional drugs to achieve synergy and to reverse tumor cell resistance. The research developments presented in this book can be translated to produce better clinical responses to resistant tumors.
Editors and Affiliations
-
Dept. Microbiology, Immunology &, Molecular Genetics, University of California, Los Angeles, Los Angeles, USA
Benjamin Bonavida
About the editor
Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.
